Literature DB >> 10604964

Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.

J H Hochman1, M Chiba, J Nishime, M Yamazaki, J H Lin.   

Abstract

Caco-2 cells grown in the presence of 1alpha,25-di-OH vitamin D(3) (di-OH vit D(3)) were used as a model to evaluate the effects of P-glycoprotein (Pgp) efflux on CYP3A4-mediated metabolism of indinavir during intestinal absorption. Caco-2 cells grown under these conditions demonstrated significant CYP3A4 activity and maintained Pgp-mediated directional transport of indinavir. Metabolism of indinavir in the di-OH vit D(3)-treated cells correlated with the level of CYP3A activity and generated metabolites consistent with CYP3A4-mediated metabolism. During transport experiments, indinavir metabolites are selectively secreted into the apical compartment, consistent with Pgp-mediated efflux. Using formation of the most abundant metabolite, M6, as a marker for indinavir metabolism, we observed that the extent of indinavir metabolism is not significantly affected by the direction of indinavir transport or by inhibition of Pgp with cyclosporin A. However, because Pgp efflux results in higher indinavir transport in the basolateral-to-apical direction than in the apical-to-basolateral direction, the ratio of M6 produced normalized to the amount of drug transported across the monolayer was higher for apical-to-basolateral transport. Thus, Pgp efflux in a direction opposite to absorptive transport results in more metabolite produced per mole of drug that is absorbed. In summary, the results support a role of Pgp in increasing intestinal presystemic metabolism and in removal of CYP3A4-generated metabolites from the intracellular compartment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604964

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model.

Authors:  S M Chung; E J Park; S M Swanson; T C Wu; W L Chiou
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

Review 2.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

3.  Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.

Authors:  Bregt S Kappelhoff; Alwin D R Huitema; Sanjay U C Sankatsing; Pieter L Meenhorst; Eric C M Van Gorp; Jan W Mulder; Jan M Prins; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

4.  Mechanistic study of the cellular interplay of transport and metabolism using the synthetic modeling method.

Authors:  Yu Liu; C Anthony Hunt
Journal:  Pharm Res       Date:  2006-01-31       Impact factor: 4.200

Review 5.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.

Authors:  Yijin Liu; Michael Jann; Chad Vandenberg; Chin B Eap; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2015-10-03       Impact factor: 4.759

7.  Membrane Assays to Characterize Interaction of Drugs with ABCB1.

Authors:  Zsolt Fekete; Zsuzsanna Rajnai; Tünde Nagy; Katalin Tauberné Jakab; Anita Kurunczi; Katalin Gémes; Krisztina Herédi-Szabó; Ferenc Fülöp; Gábor K Tóth; Maciej Czerwinski; Greg Loewen; Peter Krajcsi
Journal:  J Membr Biol       Date:  2015-04-30       Impact factor: 1.843

8.  Inhibition of the Human ABC Efflux Transporters P-gp and BCRP by the BDE-47 Hydroxylated Metabolite 6-OH-BDE-47: Considerations for Human Exposure.

Authors:  Satori A Marchitti; Christopher S Mazur; Caleb M Dillingham; Swati Rawat; Anshika Sharma; Jason Zastre; John F Kenneke
Journal:  Toxicol Sci       Date:  2016-10-23       Impact factor: 4.849

9.  Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Clin Pharmacol       Date:  2008-07-26       Impact factor: 2.953

10.  Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.

Authors:  Sarah M Robertson; Elizabeth Formentini; Raul M Alfaro; Ven Natarajan; Judith Falloon; Scott R Penzak
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.